Correction: Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

Correction: Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/6/e002262corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer
by: John Wen-Cheng Chang, et al.
Published: (2024-10-01)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
by: Ryan S. Chiang, et al.
Published: (2020-01-01)

The Impact of Age on Treatment Responses in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
by: Gülin Alkan Şen, et al.
Published: (2024-12-01)

Predictive biomarkers of response to immune checkpoint inhibitors
by: María Sacramento Díaz-Carrasco, et al.
Published: (2020-07-01)

Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
by: Tadahiro Kuribayashi, et al.
Published: (2025-01-01)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Published: (2020-10-01)

Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
by: Yanxiong Mao, et al.
Published: (2024-11-01)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Published: (2022-12-01)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
by: Kun Wang, et al.
Published: (2025-01-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer
by: Yong Zhang, et al.
Published: (2025-01-01)

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
by: Jean-François Emile, et al.
Published: (2020-05-01)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
by: Stephanie Dudzinski, et al.
Published: (2020-05-01)

Machine learning predicted fast progression after initiation of immune checkpoint inhibitors in advanced non-small cell lung cancer
by: Martin Stockler, et al.
Published: (2024-07-01)

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer
by: Nayoung Kim, et al.
Published: (2024-11-01)

Correction: Immune checkpoint inhibitor-associated celiac disease
Published: (2020-10-01)

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
by: Kartik Sehgal, et al.
Published: (2020-05-01)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
by: Yoshinori Yasuda, et al.
Published: (2022-12-01)

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
by: Chi Nguyen, et al.
Published: (2023-01-01)

Challenges and advances of immune checkpoint therapy
by: Lingyu Li, et al.
Published: (2024-12-01)

Early Alpha-Fetoprotein Response Predicts Sustained Tumor Response Following Immune Checkpoint Inhibitors Combined with Targeted Therapy in Liver Cancer
by: Jiahe Tian, et al.
Published: (2024-12-01)

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
by: Iadalin Ryntathiang, et al.
Published: (2024-09-01)

Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors
by: Yusuke Hamakawa, et al.
Published: (2025-01-01)

Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors
by: Martina Catalano, et al.
Published: (2024-11-01)

B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
by: Jean-Yves Scoazec, et al.
Published: (2024-04-01)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
by: Melissa Lumish, et al.
Published: (2020-05-01)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
by: Hao Wang, et al.
Published: (2020-05-01)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
by: Cassian Yee, et al.
Published: (2020-10-01)

Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer
by: Yaping Guan, et al.
Published: (2024-12-01)

Complete response as prognostic marker of prolonged survival in metastatic melanoma
by: D. Bafaloukos, et al.
Published: (2024-01-01)

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
by: Furnback W, et al.
Published: (2025-02-01)

Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma
by: Julian L. Goggi, et al.
Published: (2021-01-01)

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC
by: Zhenyun Yang, et al.
Published: (2024-12-01)

Circulating PD-L1 and TIM3 as Prognostic Markers in Patients With Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
by: C. Genova, et al.
Published: (2023-11-01)

Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
by: Shanmin Fan, et al.
Published: (2025-01-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Diabetic ketoacidosis as a complication of immune checkpoint inhibitor therapy
by: Nathan L. Haas, et al.
Published: (2023-06-01)

Progression of vertebral fractures in metastatic melanoma and non-small cell lung cancer patients given immune checkpoint inhibitors
by: Marco Meazza Prina, et al.
Published: (2024-12-01)

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
by: Jianyan Pan, et al.
Published: (2025-02-01)